1	Pilot randomized controlled trial of acetylsalicylic acid to reduce cerebral
2	microembolism in Chagas heart failure
3	
4	Renan Carvalho Castello-Branco ¹ , MD, MSc; Cárita Victoria Carvalho de Santana ¹ , MS;
5	Victor L. P. P. Botelho ¹ , MS; Paulo R. S. P. deSousa ¹ , MD, MSc; Maria C.P. Nunes ² , MD,
6	PhD; Karen L. Furie ³ , MD, MPH; Jamary Oliveira-Filho ¹ , MD, MSc, PhD.
7	
8	From the (1) Post-Graduate Program in Health Sciences (PPgCS), Hospital Universitario
9	Professor Edgard Santos, Federal University of Bahia, Brazil; (2) Heart Failure Clinic,
10	Hospital Universitário, Faculdade de Medicina, Universidade Federal de Minas Gerais; and
11	(3) Neurology Service, Brown University.
12	Corresponding author: Jamary Oliveira-Filho, Neurologist and Post-Graduate Program in
13	Health Sciences (PPgCS), Hospital Universitario Professor Edgard Santos, Federal University
14	of Bahia, Brazil E-mail: jamary@mail.harvard.edu. Phone: +5571981907550
15	Short Title: Microembolism and Chagas disease
16	Total word Count: 3.456
17	
18	
19	
20	
21	
22	
23	
24	Abstract:

2	Background: Chagas disease is an important cause of heart failure (HF) and stroke, affecting
3	over six million people. High intensity transient signals (HITS) are detected on transcranial
4	Doppler (TCD) in patients with Chagas disease, but the effect of antithrombotic treatment on
5	HITS is unknown. The aim of this study was to evaluate whether acetylsalicylic acid (ASA)
6	reduces the frequency and number of HITS in patients with chagasic HF. Methods: Proof-of-
7	principle pilot prospective, randomized, open and blinded endpoint clinical trial (PROBE),
8	where patients with both Chagas and HITS were randomized 2:1 to ASA 300 mg for seven
9	days and standard HF treatment or standard HF treatment alone (control group). The primary
10	outcome was the proportion of HITS after one week, analyzed using chi-squared test. Results:
11	373 patients with HF were evaluated, HITS occurred in 22/190 (12%) chagasic patients and in
12	16/183 (8%) non-chagasic patients (p=0.531). Twelve of the 22 (54%) chagasic patients were
13	randomized to treatment with ASA $(n = 8)$ or without ASA $(n = 4)$. Two patients in the
14	control group (50%) persisted with HITS after 7 days of treatment, compared to none in the
15	ASA group, p=0.028. Median number of HITS decreased from 3.5 to 0 with ASA (p=0.012)
16	and 4.0 to 0.5 in the control group (p=0.095), with no significant between-group difference
17	(p=0.262). No adverse events were reported. Conclusion: In this pilot clinical trial, ASA
18	reduced the proportion of HITS in patients with Chagas disease HF.
19	
9 10 11 12 13 14 15 16 17 18	days and standard HF treatment or standard HF treatment alone (control group). The primary outcome was the proportion of HITS after one week, analyzed using chi-squared test. Results: 373 patients with HF were evaluated, HITS occurred in 22/190 (12%) chagasic patients and in 16/183 (8%) non-chagasic patients (p=0.531). Twelve of the 22 (54%) chagasic patients were randomized to treatment with ASA (n = 8) or without ASA (n = 4). Two patients in the control group (50%) persisted with HITS after 7 days of treatment, compared to none in the ASA group, p=0.028. Median number of HITS decreased from 3.5 to 0 with ASA (p=0.012) and 4.0 to 0.5 in the control group (p=0.095), with no significant between-group difference (p=0.262). No adverse events were reported. Conclusion: In this pilot clinical trial, ASA

20 Keywords: cardiomyopathy; Chagas disease; Cerebrovascular disease, microembolisms.

1 Non-standard Abbreviations and Acronyms

- 2
- 3 ASA: acetylsalicylic acid
- 4 ELISA: Enzyme-Linked Immunosorbent Assay
- 5 IQR: Interquartile range
- 6 LVEF: Left ventricle ejection fraction
- 7 HITS: High Intensity Transient Signals
- 8 HF: Heart Failure
- 9 MCA: middle cerebral arteries
- 10 PROBE: Prospective, randomized, open-label, blinded clinical
- 11 QVSFS: Questionnaire for Verifying Stroke-Free Status
- 12 TCD: Transcranial Doppler

13

- 14
- 15
- 16
- 17
- 18
- 19 20
- 20

21

22

23 Introduction

Chagas disease affects over 6 million people worldwide, mainly in Latin American countries;
 however, migration patterns have increased infected individuals in Europe, Japan, Australia,
 Canada and the United States.¹ Victims are often infected as children and up to a third
 eventually develop cardiomyopathy for the rest of their lives, increasing the risk of sudden
 death from arrhythmias and cerebral infarction.^{2, 3}

6

7 The establishment of non-invasive methods to stratify the risk of stroke in patients with 8 Chagas disease is a priority. Additionally, it is important to define alternative outcomes to test 9 new treatments for stroke prevention in this population. Transcranial Doppler (TCD) is a 10 non-invasive and safe method that allows the identification of microembolism in the cerebral 11 circulation in real time. Inflammation and secondary activation of the hemostatic system is 12 thought to increase the risk of thrombus formation and subsequent embolic stroke, especially in the presence of structural myocardial damage such as dilated cardiomyopathy.^{4, 5} The 13 14 microembolic events are also called high intensity transient signals (HITS), visualized on 15 TCD as high intensity signals (usually> 3dB above its basal value), unidirectional, transient and with a specific sound.⁶ 16

17

In patients with heart failure (HF), HITS occur more frequently in Chagas when compared to non-Chagas patients⁷, but it is unknown whether this increased risk can be modified by antithrombotic medications. In this sense, the aim of the study was to test the effectiveness of acetylsalicylic acid (ASA) in reducing the rate of HITS in patients with Chagas-associated heart failure.

23

24 Methods

1	This was a pilot proof-of-principle prospective, randomized, open-label, blinded clinical
2	(PROBE) trial. Inclusion criteria were age above 18 years of age with HF defined according
3	to Framingham clinical criteria formed by signs (progressive edema of the lower limbs and
4	hepatomegaly not attributable to other diseases) and symptoms (dyspnea on exertion and
5	paroxysmal nocturnal dyspnea) and classified according to the New York Heart Association
6	functional class. ^{8,9} In addition, patients with Chagas disease had two positive serological tests
7	(ELISA, immunofluorescence or hemagglutination assays). Patients with a history of stroke
8	or atrial fibrillation related to cardiomyopathy were excluded.
9	
10	Exclusion criteria were designed to avoid confounding variables for transcranial Doppler
11	HITS detection, such as co-morbidities and use of oral anticoagulants. Patients with a history
12	of untreated malignant neoplasm (except localized neoplasm of the skin), ischemic
13	cerebrovascular disease (determined using the Questionnaire for Verifying Stroke-Free
14	Status), ¹⁰ chronic dialysis renal failure or end-stage liver failure were excluded. Patients with
15	HITS detected in the TCD were screened for exclusion criteria for using ASA.
16	
17	Patients screened following the inclusion / exclusion criteria underwent TCD monitoring with
18	a helmet. A single investigator performed all tests, blinded to all clinical data. The middle
19	cerebral artery was monitored continuously unilaterally for one hour looking for the
20	occurrence of HITS. Chagasic patients with HITS detected during monitoring were randomly
21	allocated 2:1 to treatment with ASA 300mg for 7 days and their usual medications for HF
22	treatment; or their medications for HF treatment alone. These patients performed a second
23	TCD after seven days verify the effectiveness of ASA in reducing HITS with an investigator
24	blinded to treatment allocation.

1

2 Statistical analysis:

3	The clinical data collected in Brazil was entered into a Research Electronic Data Capture
4	(REDCap) database and analyzed using STATA version 14.1. Demographic and clinical
5	characteristics were described as absolute and relative frequencies for categorical variables
6	and mean/standard deviation or median/interquartile range for continuous variables,
7	depending on its distribution. Normality of continuous variables were defined based on
8	Kolmogorov-Smirnov test. Based on our preliminary data on the frequency of HITS in cases
9	and controls (14% and 2%, respectively), we expected to recruit 37 chagasic patients with
10	HITS. Considering a 15% refusal rate, we expected to randomize 30 patients for ASA or
11	control treatment. With this sample size, we expected to have 80% power to detect a
12	minimum reduction of 58% in the proportion of HITS in the ASA group compared to 10% in
13	the control group. Unfortunately, the study was interrupted prematurely due to lack of
14	funding and higher than expected refusal rates.
15	
16	To compare the proportion of HITS between groups, we used chi-squared test with Yates
17	correction. As a secondary analysis, we compared the median number of emboli using Mann
18	Whitney U test. To compare the proportion of HITS between Chagas and non-Chagas groups
19	we used logistic regression analysis to control for confounding factors.
20	

The data that support the findings of this study are available from the corresponding author
upon reasonable request. The study was approved on February 13, 2014 by the ethics
committee of Professor Edgard Santos University Hospital - Federal University of Bahia,

- 1 Brazil and all patients signed informed consent. This clinical trial and its analysis plan were
- 2 registered at <u>www.clinicaltrials.gov</u> under number NCT01650792.
- 3

4 **Results**

- 5 Of the patients included in the study, 373 underwent TCD, 190 (51%) with HF Chagas
- 6 disease, median age 59 (interquartile range 35-65), 313 (83.9%) afrodescendants, 123 (65%)
- 7 females. Most frequent cerebrovascular risk factor was hypertension, present in 116 (62%)
- 8 patients. Median left ventricular ejection fraction was 42% (interquartile range 28-62).
- 9 Chagas patients less frequently had comorbidities associated with other HF etiologies such as
- 10 coronary artery disease, hypertension and diabetes. Table 1 shows the baseline characteristics
- 11 of both populations.
- 12

Of the patients who underwent TCD, 41 (11%) patients presented with HITS, observed in
22/190 (12%) of chagasic patients and in 16/183 (8.0%) of non-chagasic patients (p=0.531).
In the multivariable analysis adjusted for age, sex and left ventricle ejection fraction, Chagas
disease was not associated with HITS (odds ratio = 1.33; 95% confidence interval = 0.60 –
2.95).

18

Twelve of the 22 patients (54.5%) with Chagas disease were randomized to treatment with
ASA (n=8) or a control group (n=4). Characteristics of both groups were similar (Table 2).
The remaining patients refused consent mostly due to logistical issues (e.g., lived in a city far
from the stroke center). After seven days, two patients in the control group (50%) persisted
with HITS, while none in the ASA group persisted with HITS, p=0.028.

2	The median number of HITS decreased from 4.0 [(interquartile range (IQR) $1.3 - 6.8$) to 0.5
3	(IQR $0.0 - 4.8$) in the control group (within-group p-value=0.095); and from 3.5 (IQR $1.3 - 1.3$)
4	6.0) to none (in all patients) in the ASA-treated group (within-group p-value=0.012).
5	However, the between-group difference was not significant (p=0.262). The Figure 1 shows
6	the difference in number of HITS between days zero and seven. The figure 2 shows TCD
7	control and intervention patients at day 0 and after 7 days.

8

9 Discussion

This proof-of-concept PROBE trial was carried out to evaluate the effectiveness of ASA in 10 11 reducing the rate of cerebral microembolism in patients with chagasic HF. The main novel 12 finding was a significant reduction in the proportion of HITS from baseline TCD after seven 13 days of treatment with ASA 300mg in comparison with the control group. Additionally, 14 Chagas patients with HITS treated with ASA showed a significant reduction in the number of 15 HITS. Studies have demonstrated that antithrombotic therapy reduces the occurrence of 16 microembolism in patients with carotid atherosclerotic disease, however the effectiveness of 17 ASA in reducing the rate of HITS in patients with HF, being tested as primary prophylaxis, had not been demonstrated until now.^{11, 12} According to the Brazilian Guidelines on 18 Antiplatelets and Anticoagulant Agents in Cardiology,¹³ warfarin is indicated for primary 19 20 prevention of stroke in chagasic patients considered at high risk, such as those with left 21 ventricular thrombus or aneurysm. However, one cohort study actually identified the use of 22 ASA as risk factor for stroke in patients with heart failure, possibly due to a deleterious effect on cardiac function (Cerqueira-Silva et al., 2022).² Since our study only evaluated short-term 23

effects of ASA treatment, longer-term effects of ASA or other anti-thrombotics should be
 studied in Chagas disease before firm recommendations can be made.

3

4	Patients with chagasic cardiomyopathy presented with a numerically higher proportion of
5	HITS when compared to non-chagasic patients, data that agrees with another study, but did
6	not reach statistical significance. ⁷ Moreover, in the multivariate analysis Chagas disease was
7	not an independent risk factor for HITS in the first TCD. The other study ⁷ investigated
8	patients with higher baseline risk of HITS, such as those with a history of stroke, which we
9	could not include because these patients are usually already using anti-thrombotic
10	medications. It is possible that our study was underpowered to show a difference in
11	microembolic burden in this lower-risk population.

12

13 Other reasons for a lower-than-expected embolic risk may exist for this patient sample. Patients were vounger than most stroke cohorts and predominantly female^{7, 14} potentially 14 15 lowering microembolic burden due to cardiovascular protective effects of endogenous 16 estrogen in this age group. Patients with HF were predominantly mild/moderate functional 17 class and frequently showed preserved left ventricular ejection fraction. Several studies have 18 demonstrated a higher risk of embolism associated with reduced left ventricle ejection fraction, suggesting we selected a HF population with lower risk of embolism.^{15, 16} Chronic 19 20 inflammation in Chagas disease results in endothelial dysfunction that can stimulate the 21 hemostatic system, increasing fibrin production and platelet activation and impacting the 22 formation of microemboli, but this was not enough to account for a statistically significant increase in HITS in our sample.¹⁷⁻²⁰ 23

24

1	The limitations of the study refer to the early interruption and sample size not being reached,
2	due to the repercussions resulting from the pandemic and the long time of the study. Some
3	patients from the original cohort also suffered a stroke or died during follow-up, making them
4	unavailable for the present trial.
5	
6	In conclusion, we did not replicate the finding of a higher rate of HITS in patients with
7	Chagas disease when compared to non-Chagas patients. In the patients with Chagas disease
8	where HITS were identified, seven days of ASA treatment decreased the proportion of HITS
9	when compared to no ASA treatment. Long-term effects of primary ASA prophylaxis in
10	high-risk populations for stroke in Chagas disease should be further studied.
11	
12	Acknowledgments the Stroke Clinic, Hospital Professor Edgard Santos, Federal University
13	of Bahia, Brazil.
14	
15	Sources of Funding: None
16	
17	Disclosures: None
18	
19	
20	References:
21	1. Nunes MCP, Beaton A, Acquatella H, Bern C, Bolger AF, Echeverría LE, Dutra WO,
22	Gascon J, Morillo CA, Oliveira-Filho J, Ribeiro ALP, Marin-Neto JA. American

1		Heart Association Rheumatic Fever, Endocarditis and Kawasaki Disease Committee
2		of the Council on Cardiovascular Disease in the Young; Council on Cardiovascular
3		and Stroke Nursing; and Stroke Council. Chagas Cardiomyopathy: An Update of
4		Current Clinical Knowledge and Management: A Scientific Statement From the
5		American Heart Association. Circulation. 2018;138(12):169-209.
6		
7	2.	Cerqueira-Silva T, Gonçalves BM, Pereira CB, Porto LM, Marques ME, Santos LS,
8		Oliveira MA, Félix IF, de Sousa PRP, Muiños PJ, Maia RM, Catto MB, Andrade AL,
9		Jesus PA, Aras R, Oliveira-Filho J. Chagas disease is an independent predictor of
10		stroke and death in a cohort of heart failure patients. Int J Stroke. 2022;17(2):180-188.
11		
12	3.	Montanaro VVA, Silva GS, Oliveira Filho J, Pontes-Neto OM, do Carmo Pereira
13		Nunes M, Bezerra RP, Sousa de Melo E, Valenca Patrizia Alves de Andrade L, Alves
14		de Oliveira Junior W, Castro Alves de Meira F, Teixeira AL, Maria de Jesus Oliveira
15		E, de Freitas GR. Exploring the Chagas disease-Stroke 'Connection': Findings from a
16		Large Multicenter Study. Cerebrovasc Dis. 2024;1-5.
17		
18	4.	Aslid R, Markwalder TM, Nornes H. Noninvasive transcranial Doppler ultrasound
19		recording of flow velocity in basal cerebral arteries. J Neurosurg. 1982;57:769-774.
20		
21		
22		
23	5.	Kaposzta Z, Yong E, Bath PMW, Markus HS. Clinical application of asymptomatic
24		embolic signal detection in acute stroke: A prospective study. Stroke. 1999;1814-1818.
25		

1	6.	Edmonds HL Jr, Isley MR, Sloan TB, Alexandrov AV, Razumovsky AY. American
2		Society of Neurophysiologic Monitoring and American Society of Neuroimaging joint
3		guidelines for transcranial doppler ultrasonic monitoring. J Neuroimaging.
4		2011;21(2):177-183.
5		
6	7.	Jesus PA, Neville I, Cincurá C, Menezes DF, Vieira-de-Melo RM, Lacerda AM,
7		Viana LC, Pereira DF, Ribeiro-dos-Santos V Jr, Reis FJ, Macedo C, Oliveira-Filho J.
8		Stroke history and Chagas disease are independent predictors of silent cerebral
9		microembolism in patients with congestive heart failure. Cerebrovasc Dis.
10		2011;31(1):19-23.
11		
12	8.	McKee PA, Castelli WP, McNamara PM, Kannel WB. The natural history of
13		congestive heart failure: the Framingham study. N Engl J Med. 1971;285(26):1441-
14		1446.
15		
16	9.	Dolgin M, Association NYH, Fox AC, Gorlin R, Levin RI, New York Heart
17		Association. Criteria Committee. Nomenclature and criteria for diagnosis of diseases
18		of the heart and great vessels. 9th ed. Boston, MA: Lippincott Williams and
19		Wilkins.1994;253-256.
20		
21	10	. Jones WJ, Williams LS, Meschia JF. Validating the Questionnaire for Verifying
22		Stroke-Free Status (QVSFS) by neurological history and examination. Stroke.
23		2001;32(10):2232-2236.
24		

1	11. Junghans U, Siebler M: Cerebral microembolism is blocked by tirofiban, a selective
2	nonpeptide platelet glycoprotein IIb/IIIa receptor antagonist. Circulation. 2003;107:
3	2717-2721.
4	
5	12. Goertler M, Baeumer M, Kross R, Blaser T, Lutze G, Jost S, Wallesch CW: Cessation
6	of embolic signals after antithrombotic prevention is related to reduced risk of
7	recurrent arterioembolic transient ischaemic attack and stroke. J Neurol Neurosurg
8	Psychiatry. 2002;72:338–342.
9	
10	13. Lorga Filho AM, Azmus AD, Soeiro AM, Quadros AS, Avezum A Jr, Marques AC,
11	Franci A, Manica AL, Volschan A, De Paola AA, Greco AI, Ferreira AC, Sousa AC,
12	Pesaro AE, Simão AF, Lopes AS, Timerman A, Ramos AI, Alves BR, Caramelli B,
13	Mendes BA, Polanczyk CA, Montenegro CE, Barbosa CJ, Serrano CV Jr, Melo CC,
14	Pinho C, Moreira DA, Calderaro D, Gualandro DM, Armaganijan D, Machado Neto
15	EA, Bocchi EA, Paiva EF, Stefanini E, D'Amico E, Evaristo EF, Silva EE, Fernandes
16	F, Brito FS Jr, Bacal F, Ganem F, Gomes FL, Mattos FR, Moraes Neto FR,
17	Tarasoutchi F, Darrieux FC, Feitosa GS, Fenelon G, Morais GR, Correa Filho H,
18	Castro I, Gonçalves I Jr, Atié J, Souza Neto JD, Ferreira JF, Nicolau JC, Faria Neto
19	JR, Annichino-Bizzacchi JM, Zimerman LI, Piegas LS, Pires LJ, Baracioli LM, Silva
20	LB, Mattos LA, Lisboa LA, Magalhães LP, Lopes MA, Montera MW, Figueiredo MJ,
21	Malachias MV, Gaz MV, Andrade MD, Bacellar MS, Barbosa MR, Clausell NO,
22	Dutra OP, Coelho OR, Yu PC, Lavítola PL, Lemos Neto PA, Andrade PB, Farsky PS,
23	Franco RA, Kalil RA, Lopes RD, Esporcatte R, Heinisch RH, Kalil Filho R, Giraldez
24	RR, Alves RC, Leite RE, Gagliardi RJ, Ramos RF, Montenegro ST, Accorsi TA,
25	Jardim TS, Scudeler TL, Moisés VA, Portal VL. Diretrizes brasileiras de

1	antiagregantes plaquetários e anticoagulantes em cardiologia [Brazilian guidelines on
2	platelet antiaggregants and anticoagulants in cardiology]. Arq Bras Cardiol.
3	2013;101(3 Suppl 3):1-95.
4	
5	14. Siebler M, Kleinschmidt A, Sitzer M, Steinmetz H, Freund HJ. Cerebral
6	microembolism in symptomatic and asymptomatic high-grade internal carotid artery
7	stenosis. Neurology. 1994;44(4):615-618.
8	
9	15. Zurab G, Nadareishvili Z, Choudary Z, Joyner C, Brodie D, Worris J: Cerebral
10	microembolism in acute myocardial infarction. Stroke. 1999;30:2679–2682.
11	
12	16. Paixão LC, Ribeiro LC, Valacto RA, Teixeira AL: Chagas' disease: independent risk
13	factor for stroke. Stroke. 2009;40:3691-3694.
14	
15	17. Beamer NB, Coull BM, Clark WM, Briley DP, Wynn M, Sexton G. Persistent
16	inflammatory response in stroke survivors. Neurology. 1998;50:1722-1728.
17	
18	18. Chandrasekar B, Melby PC, toyer DA, Colston JT, Freeman GL. Temporal expression
19	of pro-inflammatory cytokines and inducible nitric oxide synthase in experimental
20	acute chagasic cardiomyopathy. Am J Pathol. 1998;152:925-934.
21	
22	19. Dutra WO, Menezes CAS, Magalhaes LMD, Gollob KJ. Immunoregulatory networks
23	in human Chagas disease. Parasite Immunol. 2014;36:377-387.
24	

- 1 20. Machado FS, Dutra WO, Esper L, Gollob KJ, Teixeira MM, Factor SM, Weiss LM,
- 2 Nagajyothi F, Tanowitz HB, Garg NJ. Current understanding of immunity to
- 3 Trypanosoma cruzi infection and pathogenesis of Chagas disease. *Semin*
- 4 *Immunopathol*. 2012;34(6):753-770.
- 5
- 6 Tables
- 7
- 8 Table 1. Baseline characteristics of patients with heart failure (HF) of Chagasic vs Non-
- 9 Chagasic etiology.

	Total	Chagas disease	Non-Chagas	p value
	(n=373)	HF	HF	
		(n=190)	(n=183)	
Age in years, median (IQR)	59 (35-65)	55 (50-61)	54 (43-63)	0.094
Female, n (%)	208 (56)	123(65)	85(46)	< 0.001
Race				< 0.001
- Asian	6 (1.6)	5 (2.6)	1 (0.5)	
- White	39 (10.4)	15 (7.9)	24 (13.1)	
- Afrodescentants	313 (83.9)	135 (71.0)	178 (97.2)	
Hypertension, n (%)	243 (65)	116 (62)	121(68)	< 0.001
Diabetes mellitus, n (%)	75(20)	33 (17)	41(23)	< 0.001
Smoking, n (%)	123 (31)	63 (33.0)	60 (33)	0.308

Use of antiplatelet agents, n (%)	87 (23)	34 (18)	49 (27)	< 0.001
Use of statins, n (%)	91 (24)	48 (25)	40 (22)	<0.001
Coronary artery disease, n (%)	73 (20)	24 (13)	47 (26)	< 0.001
Functional Class, n (%)				< 0.001
Ι	101 (29)	54 (30)	45 (28)	
П	153 (44)	81 (46)	63 (39)	
III	67 (19)	31 (18)	36 (22)	
IV	25 (7)	10 (5)	13 (8)	
Left ventricle ejection fraction in % - median (IQR)	42 (28-62)	50 (37-67)	37 (29-47)	0.919
High intensity transient signals, n (%)	41 (11%)	22 (12%)	16 (8.0%)	0.531

1

2 *IQR: Interquartile range.

3


- 4 Table 2. Primary outcome and clinical characteristics of Chagas disease patients
- 5 randomized to acetylsalicylic acid (ASA) or control groups. HITS = high-intensity
- 6 transient signals.

	Total (n=12)	ASA (n=8)	Control Group (n=4)	p value
Primary outcome:				

HITS at 7 days, n (%)	2 (16.7)	0 (0)	2 (50)	0.028
Age in years, median (IQR)	60 (55-70)	61 (57-73)	59 (52-70)	0.213
Female, n (%)	11 (92)	7 (87)	4 (100)	0.460
Race				0.221
- Asian	0 (0)	0 (0)	(0)	
- White	0 (0)	0 (0)	(0)	
- Afrodescentants	12 (100)	8 (100)	4 (100)	
Hypertension, n (%)	10 (83)	7 (87)	3 (75)	0.584
Diabetes mellitus, n (%)	2 (17)	1 (12)	1 (25)	0.584
Smoking, n (%)	0	0	0	0.679
- Smokes	0	0	0	
- Smoked	7 (58)	5 (62)	2 (50)	
- Non-smoking	5 (42)	3 (37)	2 (50)	
Use of antiplatelet agents, n (%)	3 (25)	2 (25)	1 (25)	0.764
Use of statins, n (%)	4 (33.3)	2 (25)	2 (50)	0.386
Coronary artery disease, n (%)	2 (16)	2 (25)	0 (0)	0.273
Functional Class, n (%)				0.687
I	1 (11)	1 (14)	0 (0)	
П	5 (55)	4 (57)	1 (50)	
III	2 (22)	1 (14)	1 (50)	
	1 (11)	1 (14)	0 (0)	

in % - median (IQR) 70)	Left ventricle ejection fraction	67 (60.7-	66.9 (60.7-70)	67.6(61.6-71.8)	0.358
	in % - median (IQR)	70)			

- 1 *IQR: Interquartile range.
- 2
- 3
- 4 Figure 1: Number of high-intensity transient signals (HITS) at baseline (day 0) and 7
- 5 days in acetylsalicylic acid (ASA)-treated or control group patients.



- 11 66.9%. A: Baseline TCD showing HITS; B: TCD at 7 days showing no HITS.
- 12 Patient in their 60s with Chagas disease randomized to the control group, LVEF= 73%.
- 13 C: Baseline TCD showing HITS; D: TCD at 7 days showing HITS.
- 14






Figure 1: Number of high-intensity transient signals (HITS) at baseline (day 0) and

7 days in acetylsalicylic acid (ASA)-treated or control group patients.





Patient in their 60s with Chagas disease randomized to acetylsalicylic acid use, LVEF= 66.9%. A: Baseline TCD showing HITS; B: TCD at 7 days showing no HITS.

Patient in their 60s with Chagas disease randomized to the control group, LVEF=

73%. C: Baseline TCD showing HITS; D: TCD at 7 days showing HITS.

